Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Jumped 10.7% Today

By Joe Tenebruso - Updated May 29, 2020 at 7:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech is beginning a new study for its experimental COVID-19 vaccine.

What happened

Shares of Moderna (MRNA 0.03%) rose more than 10% on Friday after the biotechnology company announced the commencement of its Phase 2 study for its novel coronavirus vaccine.

So what 

Moderna said the first participants in each age group of its Phase 2 study have received doses of its experimental COVID-19 vaccine, mRNA-1273. The study will evaluate the safety of mRNA-1273 and its ability to provoke an immune response in the human body. Participants will receive two vaccinations of mRNA-1273 spaced 28 days apart.

Moderna is seeking to enroll 600 healthy participants, including 300 people aged 18-55 and 300 people older than 55. Participants will receive either a 50 microgram dose, a 100 microgram dose, or a placebo. They will be monitored for 1 year after the second vaccination.

A person wearing productive gear working in a laboratory.

Moderna stock rose sharply on Friday after it announced the start of its Phase 2 study for its experimental coronavirus vaccine. Image source: Getty Images.

Now what 

The Phase 2 study comes after Moderna released promising early results from its Phase 1 study on May 18. Since that time, the biotech has been ramping up its production capabilities. On Thursday, Moderna extended a manufacturing agreement with CordenPharma, which will supply lipids for its COVID-19 vaccine candidate. 

Moderna also expects to begin a Phase 3 study for mRNA-1273 in July, "subject to finalization of the clinical trial protocol."

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$142.85 (0.03%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.